Transgene SA

Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001, at ESMO 2025

27 7 2025 23:30:00 提供 Nasdaq GlobeNewswire

Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independent Director

09 7 2025 08:45:00 提供 Nasdaq GlobeNewswire

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2025

08 7 2025 09:00:00 提供 Nasdaq GlobeNewswire

Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer

18 6 2025 23:00:00 提供 Nasdaq GlobeNewswire

Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders

12 6 2025 23:30:00 提供 Nasdaq GlobeNewswire

Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025

02 6 2025 23:00:00 提供 Nasdaq GlobeNewswire

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050

01 6 2025 10:15:00 提供 Nasdaq GlobeNewswire

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

22 5 2025 08:45:00 提供 Nasdaq GlobeNewswire

Transgene's Combined General Meeting of May 15, 2025

15 5 2025 08:45:00 提供 Nasdaq GlobeNewswire

Transgene Provides Business and Financial Update for Q1 2025

24 4 2025 08:45:00 提供 Nasdaq GlobeNewswire

Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025

23 4 2025 23:00:00 提供 Nasdaq GlobeNewswire

Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025

23 4 2025 08:45:00 提供 Nasdaq GlobeNewswire

Availability of Transgene’s 2024 Universal Registration Document (URD)

10 4 2025 11:15:00 提供 Nasdaq GlobeNewswire

Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations

01 4 2025 08:45:00 提供 Nasdaq GlobeNewswire

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025

27 3 2025 09:45:00 提供 Nasdaq GlobeNewswire

Transgene to Participate in Upcoming Investor Meetings

11 3 2025 09:45:00 提供 Nasdaq GlobeNewswire

Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts

06 2 2025 08:45:00 提供 Nasdaq GlobeNewswire

Transgene to Participate in the Biomed Forum Investor Conference

21 1 2025 08:45:00 提供 Nasdaq GlobeNewswire

Transgene Announces Financial Calendar for 2025

14 1 2025 08:45:00 提供 Nasdaq GlobeNewswire

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024

07 1 2025 09:00:00 提供 Nasdaq GlobeNewswire